Tryp Therapeuatics (TRYPF) Coverage Report

For Tryp, its Phase 2a’s will have a six-month office visit to assess safety and efficacy.  Societal views of psychedelics. And finally, given psychedelics sharp exit from the medical community ~50 years ago and the subsequent opinions that many have about hallucinations, it is important in our view to consider the current state of potential opinions on psychedelics when gauging market adoption. From our review, we find increasing support for psychedelics and do not expect a noticeable impediment in adoption, especially among the patients with a condition considered to have a high unmet need, such as eating disorders and chronic pain. o According to a National Survey on Drug Use and Health survey of Americans almost 20 years ago (2001 to 2004; ~130,000 respondents), it was estimated that >30M Americans had used LSD, psilocybin or mescaline (www.samhsa.gov; PLoS One. 2013; 8(8): e63972). We were surprised it was that high but found it has since increased. o The most recently published survey (Oct. ’20) includes data into 2019 and found among those 12+ past year hallucinogen use increased from 1.8% (4.7M) in 2015 to ~2.2% (~6.0M) in 2018 and 2019. In 2019, among the 12–17-year-olds, 1.8% reported past-year use of hallucinogens. o Across the five most recent years in this survey, the 18-to-25-year-old group had the highest past year use, which held steady (~7%). Meanwhile, those >26 doubled from 0.8% to 1.5%, with 259,000 in this age trying hallucinogens for the first time in 2019, which was a similar number every year since 2015. Michael Higgins 212.409.2074 Tryp Therapeutics, Inc. (TRYPF) Page 9